Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib

Overview of attention for article published in Targeted Oncology, October 2017

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 26 Dimensions

Readers on

mendeley: 39 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 291 followers.

Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma with the Second-Generation ALK Inhibitor Ceritinib https://t.co/jJBTuXdStD

Reply Repost Favourite